Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting
Verrica Pharmaceuticals presented Phase 2 data at the SID Annual Meeting showing that its oncolytic peptide VP-315 reduced the size of untreated basal cell carcinoma lesions by an average of 67%, suggesting a systemic abscopal effect. In the study of 14 untreated lesions across 9 subjects, 21% achieved complete histologic clearance, indicating the drug may trigger broader immune activation beyond the injection site.
Key figures
- Drug Name
- VP-315 (ruxotomitide)
- Phase Of Trial
- Phase 2
- Bcc incidence annual us
- 3.6 million
- Untreated lesion reduction avg
- 67%
- Untreated lesion complete clearance
- 21%
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.